171 related articles for article (PubMed ID: 10326705)
1. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry.
Nakaguchi H; Fujimaki T; Matsuno A; Matsuura R; Asai A; Suzuki I; Sasaki T; Kirino T
Cancer; 1999 May; 85(10):2249-54. PubMed ID: 10326705
[TBL] [Abstract][Full Text] [Related]
2. MIB-1 staining index and peritumoral brain edema of meningiomas.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Cancer; 1996 Jul; 78(1):133-43. PubMed ID: 8646709
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
6. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
7. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
8. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
9. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
10. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
12. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
13. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma.
Nishi T; Kuratsu J; Takeshima H; Saito Y; Kochi M; Ushio Y
Int J Mol Med; 1999 Feb; 3(2):157-61. PubMed ID: 9917523
[TBL] [Abstract][Full Text] [Related]
18. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
19. [Report of seven cases of clear-cell meningioma and a literature review].
Rousselot C; Francois P; Jan M; Bergemer AM
Ann Pathol; 2010 Apr; 30(2):73-82. PubMed ID: 20451062
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]